Literature DB >> 21336122

Glucose absorption and small intestinal transit in critical illness.

Adam M Deane1, Matthew J Summers, Antony V Zaknic, Marianne J Chapman, Anna E Di Bartolomeo, Max Bellon, Anne Maddox, Antoinette Russo, Michael Horowitz, Robert J L Fraser.   

Abstract

OBJECTIVES: Although enteral nutrition is standard care for critically ill patients, nutrient absorption has not been quantified in this group and may be impaired due to intestinal dysmotility. The objectives of this study were to measure small intestinal glucose absorption and duodenocecal transit and determine their relationship with glycemia in the critically ill.
DESIGN: Prospective observational study of healthy and critically ill subjects.
SETTING: Tertiary mixed medical-surgical adult intensive care unit.
SUBJECTS: Twenty-eight critically ill patients and 16 healthy subjects were studied. MATERIALS AND MAIN
RESULTS: Liquid feed (100 kcal/100 mL), labeled with Tc-sulfur colloid and including 3 g of 3-O-methylglucose, was infused into the duodenum. Glucose absorption and duodenocecal transit were measured using the area under the 3-O-methylglucose concentration curve and scintigraphy, respectively. Data are median (range). RESULTS AND DISCUSSION: Glucose absorption was reduced in critical illness when compared to health (area under the concentration curve: 16 [1-32] vs. 20 [14-34] mmol/L·min; p = .03). Small intestinal transit times were comparable in patients and healthy subjects (192 [9-240] vs. 168 [6-240] min; p = .99) and were not related to glucose absorption. Despite higher fasting blood glucose concentrations (6.3 [5.1-9.3] vs. 5.7 [4.6-7.6] mmol/L; p < .05), the increment in blood glucose was sustained for longer in the critically ill (Δ glucose at t = 60; 1.9 [-2.1-5.0] mmol/L vs. -0.2 [-1.3-2.3] mmol/L; p < .01).
CONCLUSIONS: Critical illness is associated with reduced small intestinal glucose absorption, but despite this, the glycemic response to enteral nutrient is sustained for longer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21336122     DOI: 10.1097/CCM.0b013e31820ee21f

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  16 in total

Review 1.  Gastrointestinal Dysfunction and Feeding Intolerance in Critical Illness: Do We Need an Objective Scoring System?

Authors:  Stephen A McClave; Jill Gualdoni; Annie Nagengast; Luis S Marsano; Kathryn Bandy; Robert G Martindale
Journal:  Curr Gastroenterol Rep       Date:  2020-01-07

2.  Mesenteric blood flow, glucose absorption and blood pressure responses to small intestinal glucose in critically ill patients older than 65 years.

Authors:  Jennifer A Sim; M Horowitz; M J Summers; L G Trahair; R S Goud; A V Zaknic; T Hausken; J D Fraser; M J Chapman; K L Jones; A M Deane
Journal:  Intensive Care Med       Date:  2012-10-25       Impact factor: 17.440

3.  Gastric emptying measurement of liquid nutrients using the (13)C-octanoate breath test in critically ill patients: a comparison with scintigraphy.

Authors:  Nam Q Nguyen; Laura K Bryant; Carly M Burgstad; Marianne Chapman; Adam Deane; Max Bellon; Kylie Lange; Dylan Bartholomeuz; Michael Horowitz; Richard H Holloway; Robert J Fraser
Journal:  Intensive Care Med       Date:  2013-03-08       Impact factor: 17.440

4.  Decision support for optimized blood glucose control and nutrition in a neurotrauma intensive care unit: preliminary results of clinical advice and prediction accuracy of the Glucosafe system.

Authors:  Ulrike Pielmeier; Mark Lillelund Rousing; Steen Andreassen; Birgitte Steenfeldt Nielsen; Pernille Haure
Journal:  J Clin Monit Comput       Date:  2012-05-13       Impact factor: 2.502

5.  Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study.

Authors:  Palash Kar; Caroline E Cousins; Christopher E Annink; Karen L Jones; Marianne J Chapman; Juris J Meier; Michael A Nauck; Michael Horowitz; Adam M Deane
Journal:  Crit Care       Date:  2015-01-23       Impact factor: 9.097

6.  The relationship between fasting plasma citrulline concentration and small intestinal function in the critically ill.

Authors:  Alexis Poole; Adam Deane; Matthew Summers; Janice Fletcher; Marianne Chapman
Journal:  Crit Care       Date:  2015-01-20       Impact factor: 9.097

7.  The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial.

Authors:  Marianne J Chapman; Adam M Deane; Stephanie L O'Connor; Nam Q Nguyen; Robert J L Fraser; Duncan B Richards; Kimberley E Hacquoil; Lakshmi S Vasist Johnson; Matthew E Barton; George E Dukes
Journal:  Crit Care       Date:  2016-08-01       Impact factor: 9.097

Review 8.  An Iranian Consensus Document for Nutrition in Critically Ill Patients, Recommendations and Initial Steps toward Regional Guidelines.

Authors:  Seyed Mohammadreza Hashemian; Robert G Martindale; Hamidreza Jamaati; Ali Amirsavadkouhi; Salahaddin Mahmudi Azer; Mahdi Shadnoush; Seyed Hossein Ardehali; Atabak Najafi; Arezoo Ahmadi; Seyyed Reza Seyyedi; Ata Mahmoodpoor; Omid Moradi; Saeed Abbasi; Saeed Hosseini; Reza Shahrami; Saeed Abdi; Zahra Sepehri; Babak Omranirad; Seyed Amir Mohajerani; Pejman Rohani; Aliakbar Sayyari; Hossein Imani; Ali Akbar Velayati
Journal:  Tanaffos       Date:  2017

9.  Comparative effects on glucose absorption of intragastric and post-pyloric nutrient delivery in the critically ill.

Authors:  Anna E Di Bartolomeo; Marianne J Chapman; Antony V Zaknic; Matthew J Summers; Karen L Jones; Nam Q Nguyen; Christopher K Rayner; Michael Horowitz; Adam M Deane
Journal:  Crit Care       Date:  2012-09-17       Impact factor: 9.097

10.  Disordered control of intestinal sweet taste receptor expression and glucose absorption in type 2 diabetes.

Authors:  Richard L Young; Bridgette Chia; Nicole J Isaacs; Jing Ma; Joan Khoo; Tongzhi Wu; Michael Horowitz; Christopher K Rayner
Journal:  Diabetes       Date:  2013-06-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.